Clinicopathological analysis of recurrence patterns and prognostic factors for survival after hepatectomy for colorectal liver metastasis

Hayashi, Michihiro; Inoué, Yoshihiro; Koyama, Koji; Shimizu, Tetsunosuke; Asakuma, Mitsuhiro; Hirokawa, Fumitoshi; Miyamoto, Yoshiharu; Okuda, Jun; Takeshita, Atsushi; Shibayama, Yuro; Tanigawa, Nobuhiko

doi:10.1186/1471-2482-10-27

Cited by 89 publications

(71 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…5,15 Certain clinicopathologic factors, such as the presence of extrahepatic metastases, the presence of more than 3 tumors, and a disease-free interval of less than 12 months, have been associated with a poor prognosis in patients with CRC. 12,[16][17][18][19][20] …”

mentioning

confidence: 99%

Colon Cancer, Version 3.2014

Benson¹,

Venook²,

Bekaii‐Saab³

et al. 2014

J Natl Compr Canc Netw

200

171

View full text Add to dashboard Cite

OverviewColorectal cancer (CRC) is the fourth most frequently diagnosed cancer and the second leading cause of cancer death in the United States. In 2013, an estimated 102,480 new cases of colon cancer and approximately 40,340 cases of rectal cancer will occur. During the same year, an estimated 50,830 people will die of colon and rectal cancers combined. AbstractThe NCCN Guidelines for Colon Cancer address diagnosis, pathologic staging, surgical management, perioperative treatment, posttreatment surveillance, management of recurrent and metastatic disease,and survivorship. This portion of the guidelines focuses on the use of systemic therapy in metastatic disease. The management of metastatic colorectal cancer involves a continuum of care in which patients are exposed sequentially to a variety of active agents, either in combinations or as single agents. Choice of therapy is based on the goals of treatment, the type and timing of prior therapy, the different efficacy and toxicity profiles of the drugs, the mutational status of the tumor, and patient preference. (J Natl Compr Canc Netw 2014;12:1028-1059 NCCN Categories of Evidence and ConsensusCategory 1: Based upon high-level evidence, there is uniform NCCN consensus that the intervention is appropriate. Category 2A: Based upon lower-level evidence, there is uniform NCCN consensus that the intervention is appropriate. Category 2B: Based upon lower-level evidence, there is NCCN consensus that the intervention is appropriate. Category 3: Based upon any level of evidence, there is major NCCN disagreement that the intervention is appropriate. These guidelines are also available on the Internet. For the latest update, visit NCCN.org.

show abstract

mentioning

confidence: 99%

Colon Cancer, Version 3.2014

Benson¹,

Venook²,

Bekaii‐Saab³

et al. 2014

J Natl Compr Canc Netw

200

171

View full text Add to dashboard Cite

show abstract

“…Preoperatively volumetric imaging of the liver is obtained in order to evaluate the size of the remnant liver, which, if inadequate can be expanded with portal vein embolization of the segments to be resected. The presence of extrahepatic metastases and a disease-free interval of less than 12 months after hepatic resection have been proposed as poor prognosis indicators but their role is yet to be confirmed [48]. Palliative resection of the primary in case of synchronous metastases and surgical debulking provide no survival benefit and are indicated only for symptomatic disease (imminent obstruction or acute significant bleeding), with systemic chemotherapy considered the preferred initial approach [49].…”

Section: Metastatic Rectal Cancermentioning

confidence: 99%

Updates on Rectal Cancer

Zoccali

Krane

Fichera

2011

Curr Colorectal Cancer Rep

View full text Add to dashboard Cite

In the last few decades there has been a shift in the paradigm of rectal cancer treatment. Surgery, historically the only weapon against rectal malignances, has found valuable allies in other treatment modalities, extending the range of cure to previously untreatable stages of disease. Perioperative protocols have led to a dramatic improvement in local control of locally advanced disease. The integration of targeted therapies with more effective cytotoxic protocols and refined surgical strategies has expanded the treatment of metastatic disease, resulting in improved survival. Advances in risk stratification will allow us to identify patients who may benefit from conservative surgical approaches in the future. This manuscript reviews the accepted standard of care protocols and highlights areas currently under debate.

show abstract

“…In reality, despite the implementation of all possible therapeutic methods, 25-50% of patients with colorectal cancer stage I and II present with cancer recurrence (6). Therefore, the search for prognostic factors which would accurately determine the likelihood of recurrence.…”

mentioning

confidence: 99%